Double blind clinical trial on the use of ultra-levure in the prophylaxis of antibiotic induced gastro-intestinal and mucocutaneous disorders.
DOI:
https://doi.org/10.20344/amp.3879Abstract
Em 240 doentes de diversas idades e patologias foi administrado simultaneamente com um antibiótico oral (tetraciclina ou betalactamina), quer um concentrado de Saccharomyces Boulardii (Ultra-levure) — 121 doentes, quer um placebo – 119 doentes. A percentagem de doentes em que surgiu alteração do trânsito intestinal (mais de 2 dejecções por dia) foi de 27.7% no grupo que tomou o placebo e 15.7% no grupo que tornou Ultralevure; a percentagem de doentes em que surgiu candidíase cutânea ou mucosa foi de 10.7% no primeiro grupo e 1.7% no segundo. Ambas as diferenças são significativas, respectivamente P <0.025 e P <0.10.
Downloads
Downloads
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
